FDA Grants Accelerated Approval to J&J Subcutaneous Rybrevant Faspro for Head and Neck Cancer

Head and neck squamous cell carcinoma is a group of aggressive cancers that arise in the mouth, throat, larynx and related structures, and it has long been one of the harder solid tumors to treat once it returns or spreads. The FDA describes the disease as aggressive and life threatening, with a high unmet need for effective therapies. Pharmaceutical Executive reported on November 6, 2026 that HNSCC accounts for roughly 4.5 percent of cancer diagnoses worldwide and ranks seventh in incidence, with tobacco, alcohol and high-risk HPV infection as the major risk factors.

For patients whose disease progresses after platinum-based chemotherapy and an anti-PD-(L)1 antibody, the historical options have been bleak. The FDA said currently approved therapies in this setting are associated with an overall response rate of around 20 percent or less and poor outcomes. The agency also characterized the November 5 decision as the first approval in 10 years of a drug for patients with recurrent or metastatic HNSCC who had received prior platinum-based chemotherapy.

Rybrevant is not a new molecule. Intravenously infused Rybrevant was initially approved in 2021 for non-small cell lung cancers harboring an EGFR mutation, and in 2024 the FDA approved J&J's Lazcluze, an oral small molecule EGFR inhibitor, for use with Rybrevant. MedCity News reported on November 6, 2026 that FDA approval of Rybrevant Faspro in December 2025 covered all of the indications at the time for IV-infused Rybrevant. The Faspro formulation pairs amivantamab with Halozyme's ENHANZE recombinant human hyaluronidase PH20 technology, which allows the antibody to be given as a subcutaneous injection.

On November 5, 2026, the FDA granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as a single agent for adults with recurrent or metastatic HNSCC whose disease progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody. Johnson & Johnson announced the approval the same day, calling the product the first and only dual-targeted therapy for advanced head and neck cancer. The approval was granted to Janssen Biotech, Inc.

Key Facts

The FDA said the decision rests on an open-label, multicenter trial involving 102 patients. The ASCO Post reported on November 6, 2026 that efficacy was evaluated in the multi-cohort OrigAMI-4 trial, registered as NCT06385080, with patients receiving single-agent weight-based subcutaneous dosing every three weeks at the recommended dose until disease progression or unacceptable toxicity. The primary efficacy population excluded patients with HPV-associated oropharyngeal squamous cell carcinoma based on p16 testing, and eligible patients had to have received prior platinum-based chemotherapy and an anti-PD-(L)1 antibody. The recommended dose is weight-based, and the product is supplied as a subcutaneous injection of 160 mg/2,000 units per mL.

Confirmed overall response rate was 42 percent (95 percent CI, 32 to 52 percent) by blinded independent central review according to RECIST v1.1. Johnson & Johnson said on November 5, 2026 that the response included complete responses in 15 percent of patients, representing one-third of all responders, and partial responses in 28 percent. Fifty-six percent of responders maintained a response for more than six months, with a range of 1.4+ to 19.7+ months. The FDA framed the result as more than double the percentage of patients responding compared with currently approved therapies.

Safety was not benign. Pharmaceutical Executive reported on November 6, 2026 that the most common adverse reactions occurring in at least 20 percent of patients were rash (79 percent), fatigue (39 percent), nail toxicity (35 percent), stomatitis (32 percent) and edema (28 percent). Serious adverse reactions occurred in 39 percent of patients, and 6 percent had fatal adverse reactions, including sudden death in 2 percent and single cases of myocardial ischemia, tumor hemorrhage, aspiration pneumonia and interstitial lung disease. The company reports no new safety signals versus prior Rybrevant Faspro experience.

The labeling carries warnings and precautions for hypersensitivity and administration-related reactions, interstitial lung disease or pneumonitis, dermatologic adverse reactions, ocular toxicity and embryo-fetal toxicity. The indication explicitly excludes HPV-associated oropharyngeal squamous cell carcinoma identified by p16 immunohistochemistry. The FDA granted Breakthrough Therapy designation for this indication, following a February 2026 designation and a Priority Review in July 2026, and the review was conducted under Project Orbis with regulators in Brazil (ANVISA), Canada (Health Canada), Israel (IMoH) and Singapore (HSA).

Analysis

The headline number is strong, but the evidence base is narrow. OrigAMI-4 is a single-arm, open-label cohort, so the 42 percent response rate cannot be compared directly with other options, and the company's announcement did not report survival outcomes. Pharmaceutical Executive noted that in a 2016 phase 3 trial of platinum-refractory disease, nivolumab produced median overall survival of 7.5 months versus 5.1 months with standard single-agent therapy. A response rate is not the same thing as added months of life, and regulators accepted it here only because the unmet need is severe and the accelerated pathway allows confirmatory work to run in parallel.

What this really means is that the approval is a conditional bet, not a finished verdict. Continued approval may be contingent on the ongoing Phase 3 OrigAMI-5 confirmatory trial, which evaluates subcutaneous Rybrevant Faspro with carboplatin and pembrolizumab as first-line treatment. That is a different setting and a different regimen from the second-line single-agent use just approved, which is a meaningful distinction for anyone reading the data as a promise of first-line benefit. The confirmatory program will have to deliver on a population that is not identical to the one that generated the 42 percent figure.

Commercially, the decision matters well beyond head and neck cancer. MedCity News reported on November 6, 2026 that the Rybrevant and Lazcluze franchise grew 67.4 percent to $866 million in the first nine months of 2026, and that the company has projected Rybrevant could reach $5 billion in peak sales. This is the first indication beyond non-small cell lung cancer for Rybrevant Faspro, so the approval tests whether the franchise can travel outside its original EGFR-mutant lung cancer beachhead. The dual EGFR and MET mechanism is the selling point: J&J says the two pathways are overexpressed in 80 to 90 percent of recurrent and metastatic HNSCC tumors and often associated with poor prognosis.

The bigger picture here is that delivery format has become part of the clinical value proposition. Rybrevant Faspro is given as a five-minute subcutaneous injection, compared with two to five hours for an intravenous infusion of the older formulation. For a population with poor performance status and limited life expectancy, time in a chair is not a trivial detail, and it is the kind of incremental change that can matter as much as a response rate when clinicians decide what to use.

Why It Matters

Patients in this setting have had few good options. The FDA's Angelo De Claro, M.D., director of the Oncology Center of Excellence, said the approval represents a meaningful step forward for patients with limited options. The agency's own framing, that currently approved therapies yield an overall response rate of around 20 percent or less, sets the baseline against which the 42 percent figure will be judged in practice. The gap between those numbers is the reason the application received Breakthrough Therapy designation and Priority Review.

J&J estimates that about 80 percent of recurrent or metastatic cases are not HPV-driven and typically carry a poorer prognosis, which is the group the label targets by excluding HPV-associated oropharyngeal disease. Head and neck cancer is not a rare disease, and the seventh-ranked incidence figure means the eligible population is large enough to support a commercial franchise even after the p16 exclusion. The approval also gives clinicians a dual-targeted option in a field where single-agent chemotherapy and checkpoint inhibitors have dominated.

The safety profile will shape how quickly that option is adopted. Rash in 79 percent of patients, serious adverse reactions in 39 percent and fatal adverse reactions in 6 percent are not small numbers, and they put a premium on patient selection and monitoring. The warnings for interstitial lung disease, ocular toxicity and embryo-fetal toxicity are standard for this class but still require careful management in a population that may already be fragile.

Next Up

The immediate focus is OrigAMI-5. The Phase 3 confirmatory trial evaluates subcutaneous Rybrevant Faspro with carboplatin and pembrolizumab as first-line treatment, and its results will determine whether the accelerated approval converts into a full approval and whether the regimen can move earlier in the treatment sequence. The pivotal results behind the current approval were presented at ASCO 2026 and published in the Journal of Clinical Oncology.

Internationally, the Project Orbis review means regulators in Brazil, Canada, Israel and Singapore were working alongside the FDA, so additional decisions in those markets are the next thing to watch. For now, the label stands as a single-agent, second-line option for adults whose disease progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody, with the HPV-associated oropharyngeal exclusion written directly into the indication.